ArticleOncoTargets and therapy2018
Knockdown of KIF26B inhibits breast cancer cell proliferation, migration, and invasion.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prognostic significance of the kinesin superfamily in breast cancer: A systematic review & meta-analysis.The Indian journal of medical research · 2025Pooled it
- From Motor Proteins to Oncogenic Factors: The Evolving Role of Kinesin Superfamily Proteins in Breast Cancer Development.Molecular biotechnology · 2026Review
- Low KIF26B Expression Reduces Paclitaxel Resistance and Predicts Good Prognosis in Ovarian Cancer.Current issues in molecular biology · 2026Article
- Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance.Cancer biology & therapy · 2024Review
- KIF14 affects cell cycle arrest and cell viability in cervical cancer by regulating the p27World journal of surgical oncology · 2022Article
- Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer.Bioengineered · 2022Article
- Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer.Cancer cell international · 2022Article
- Fusobacterium nucleatum reduces METTL3-mediated mNature communications · 2022Article
- KIF26B in the Prognosis and Immune Biomarking of Various Cancers: A Pan-Cancer Study.Journal of oncology · 2022Article
- KIF26B Is Overexpressed in Medulloblastoma and Promotes Malignant Progression by Activating the PI3K/AKT Pathway.Analytical cellular pathology (Amsterdam) · 2022Article
- ELK1-induced up-regulation of KIF26B promotes cell cycle progression in breast cancer.Medical oncology (Northwood, London, England) · 2021Article
- Association of a NovelIranian journal of public health · 2021Article
- Kinesin superfamily protein 21B acts as an oncogene in non-small cell lung cancer.Cancer cell international · 2020Article
- Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13).Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway.Cancer cell international · 2019Article
- miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6.OncoTargets and therapy · 2019Article
- MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells.OncoTargets and therapy · 2018Article
- Noncoding RNAs-based high KIF26B expression correlates with poor prognosis and tumor immune infiltration in colon cancer.Cell cycle (Georgetown, Tex.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKinesin family member 26B (KIF26B) plays a key role in the development and progression of many human cancers. However, the role and underlying mechanisms of KIF26B in breast cancer cells remain unknown. MATERIALS AND
methodsIn this study, we inhibited the expression of KIF26B in MDA-MB-231 and MCF-7 cells using lentivirus-delivered shRNA.
resultsLentivirus-mediated KIF26B knockdown significantly suppressed cell proliferation, colony formation, migration, and invasion. Furthermore, cell cycle analyses revealed that the percentage of cells in the G0/G1 phase was significantly increased in KIF26B knockdown cells. Moreover, the knockdown of KIF26B significantly promoted cell apoptosis via the upregulation of cleaved caspase-3 and Bax.
conclusionOur data indicate that KIF26B plays a pivotal role in tumor growth and metastasis in breast cancer cells and may be a potential therapeutic target for treating breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.